AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

Indegene launches new center in London

Financial Times names Indegene among high-growth companies in Asia-Pacific 2025

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products

Croda opens advanced lipids manufacturing facility in Pennsylvania

This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’

Anupriya Patel inaugurates India Innovation Summit – Pioneering Solutions to End TB

TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023

Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset

This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care

Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M